Quick Answer
Kura Oncology, Inc. reported Operating Income Loss of -$303.63 million for the year ending 2025.
- Kura Oncology, Inc. showed a decrease of -57.2% in Operating Income Loss from 2024 to 2025.
- This data is from Kura Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2010 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: -$5.1 thousand | Q3 2010: -$4.2 thousand | Q1 2011: -$4.3 thousand | Q2 2011: -$5.8 thousand | Q3 2011: -$5.4 thousand | Q1 2012: -$4.2 thousand | Q2 2012: -$5.0 thousand | Q3 2012: -$4.7 thousand | Q1 2013: -$4.7 thousand | Q2 2013: -$5.5 thousand | Q3 2013: -$4.5 thousand | Q1 2014: -$4.1 thousand | Q2 2014: -$5.2 thousand | Q3 2014: -$4.8 thousand | Q1 2024: -$54.45 million | Q2 2024: -$56.40 million | Q3 2024: -$59.88 million | Q1 2025: -$64.70 million | Q2 2025: -$72.67 million | Q3 2025: -$80.00 million.
- Over the full 9 years of available data (2010 to 2025), Kura Oncology, Inc.'s Operating Income Loss has declined by 1,480,376.9%.
- Historical annual values: Fiscal year 2025: -$303.63 million | Fiscal year 2024: -$193.20 million | Fiscal year 2023: -$165.80 million | Fiscal year 2022: -$139.87 million | Fiscal year 2014: -$23.9 thousand | Fiscal year 2013: -$22.7 thousand | Fiscal year 2012: -$22.3 thousand | Fiscal year 2011: -$23.4 thousand | Fiscal year 2010: -$20.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: